Skip to content

ESMO 2017 – Day 1 – Highlights

  • by

Review the Highlights of the Day: latest news, developments, trends and studies, ideas and perspectives, 23’000 clinicians and researchers here at Madrid.

As ma always brings very good news i wish to hear something breaking around collect your cancer in gastric the new developments in amino oncology as well as part of a new vision new trends new you know studies which are matured rate of breaking abstract new nivel drugs here nice new ideas and perspectives useful and for me and for my patients 23,000 clinicians and

Researchers are here in madrid from 8 to 12 september more than 250 sessions will guide attendees through the latest breakthroughs from research and the most promising therapies providing tips for daily practice and discussing controversial issues in the field i think it’s important to translate what the academics are doing it has to be translated to clinical

Practice the researchers developed the the potential new treatments that need to be converted to treatments into humans cooperation will be a key driver for oncology in the future for this as moe has dedicated its annual meeting to the integration of basic research into clinical practice aiming to close the gap between two different categories of professionals

For a better patient outcome in this direction this year’s congress is held for the first time in partnership with the european association for cancer research as moe is home for everyone who wants to build bridges commented esma president fortunato giardello in his welcome message during the opening ceremony concert one dream on any one of us all together

Becomes a dream of all of us together regardless of our origin our background we come from 131 different countries in the world all together for the same we start step-by-step to go all together to become one yeah and we do that often across oncology or while without any limitation without the smaller the tumor the better the prognosis this is likely to be

Untrue when it comes to early breast cancer as suggested by a sub analysis from the mind act trial which was presented today in madrid investigators reported that one of four women with small node negative tumors who had a low clinical risk at the beginning of the trial due to their nodule being less than one centimeter benefited from chemotherapy and showed

Higher rates of disease-free survival overall survival and distant metastasis free survival five years later these results are consistent with the fact that twenty four percent of small tumors were found to have an aggressive biology node-negative disease is a prevalent form of breast cancer worldwide and the administration of adjuvant chemotherapy is still

Controversial the study shows that assessing clinical risk together with tumor biology by using a 70 gene signature can potentially guide clinical choices how do patients perceive scientific breakthroughs in oncology and why is their involvement and research so relevant today the patient’s advocacy jacket as moe 2017 provides an invaluable opportunity to find

Some answers it is really important to include patients into the beginning in the clinical trials to decide the most important the clinical endpoint but also at the end of the studies the two interpretated the clinical results and the safety of the clinical trials in 2017 the patient is in a different position than before and the he’s able through internet and

Through also all the press and all the newspapers to know much better what are the outcomes of the clinical trial so it is very important to share the information with the oncologist directly and try to interpretate if the results are really in line on what patients they really want there is a big lack of research on this field and we have to foster research

To better understand the patient reported outcomes what really the patient’s want for their life and how to create some instruments to better interpret the clinical trial results

Transcribed from video
ESMO 2017 – Day 1 – Highlights By European Society for Medical Oncology